Kezar Life Sciences Stock Performance
| KZR Stock | USD 5.89 0.31 5.56% |
The company secures a Beta (Market Risk) of 0.66, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Kezar Life's returns are expected to increase less than the market. However, during the bear market, the loss of holding Kezar Life is expected to be smaller as well. At this point, Kezar Life Sciences has a negative expected return of -0.11%. Please make sure to verify Kezar Life's potential upside and day median price , to decide if Kezar Life Sciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Kezar Life Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. Even with latest unsteady performance, the Stock's basic indicators remain invariable and the latest agitation on Wall Street may also be a sign of long-running gains for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return 5.56 | Five Day Return 0.68 | Year To Date Return (10.35) | Ten Year Return (99.67) | All Time Return (99.67) |
Last Split Factor 1:10 | Last Split Date 2024-10-30 |
1 | Acquisition by Christopher Kirk of 120000 shares of Kezar Life at 6.58 subject to Rule 16b-3 | 01/08/2025 |
2 | Acquisition by Klearman Micki of 52000 shares of Kezar Life at 2.28 subject to Rule 16b-3 | 01/15/2025 |
3 | Kezar Life Sciences Files 400 Million Mixed Securities Shelf -February 05, 2025 at 0555 pm EST - Marketscreener.com | 02/05/2025 |
4 | Acquisition by Marc Belsky of 90000 shares of Kezar Life at 2.28 subject to Rule 16b-3 | 02/11/2025 |
5 | Acquisition by John Fowler of 5000 shares of Kezar Life at 5.89 subject to Rule 16b-3 | 02/14/2025 |
6 | Kezar stock rating raised to Outperform at William Blair - Investing.com | 02/28/2025 |
7 | Acquisition by Mark Schiller of 7200 shares of Kezar Life at 6.3 subject to Rule 16b-3 | 03/04/2025 |
8 | Acquisition by Garner Elizabeth of 26000 shares of Kezar Life at 2.28 subject to Rule 16b-3 | 03/06/2025 |
| Begin Period Cash Flow | 40.5 M |
Kezar |
Kezar Life Relative Risk vs. Return Landscape
If you would invest 644.00 in Kezar Life Sciences on December 22, 2024 and sell it today you would lose (55.00) from holding Kezar Life Sciences or give up 8.54% of portfolio value over 90 days. Kezar Life Sciences is generating negative expected returns assuming volatility of 2.5574% on return distribution over 90 days investment horizon. In other words, 22% of stocks are less volatile than Kezar, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Kezar Life Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kezar Life's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kezar Life Sciences, and traders can use it to determine the average amount a Kezar Life's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0446
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KZR |
Estimated Market Risk
| 2.56 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.11 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Kezar Life is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kezar Life by adding Kezar Life to a well-diversified portfolio.
Kezar Life Fundamentals Growth
Kezar Stock prices reflect investors' perceptions of the future prospects and financial health of Kezar Life, and Kezar Life fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kezar Stock performance.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | (87.84 M) | ||||
| Shares Outstanding | 7.3 M | ||||
| Price To Earning | (9.34) X | ||||
| Price To Book | 0.33 X | ||||
| Price To Sales | 6.12 X | ||||
| Revenue | 7 M | ||||
| Gross Profit | (72.35 M) | ||||
| EBITDA | (99.25 M) | ||||
| Net Income | (101.87 M) | ||||
| Cash And Equivalents | 306.84 M | ||||
| Cash Per Share | 4.49 X | ||||
| Total Debt | 18.93 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 39.64 X | ||||
| Book Value Per Share | 18.37 X | ||||
| Cash Flow From Operations | (81.64 M) | ||||
| Earnings Per Share | (13.12) X | ||||
| Market Capitalization | 42.97 M | ||||
| Total Asset | 221.24 M | ||||
| Retained Earnings | (350.76 M) | ||||
| Working Capital | 189.21 M | ||||
| Current Asset | 74.47 M | ||||
| Current Liabilities | 2.18 M | ||||
About Kezar Life Performance
Assessing Kezar Life's fundamental ratios provides investors with valuable insights into Kezar Life's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Kezar Life is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 543.87 | 377.62 | |
| Return On Tangible Assets | (0.41) | (0.44) | |
| Return On Capital Employed | (0.47) | (0.49) | |
| Return On Assets | (0.41) | (0.44) | |
| Return On Equity | (0.62) | (0.59) |
Things to note about Kezar Life Sciences performance evaluation
Checking the ongoing alerts about Kezar Life for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kezar Life Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kezar Life Sciences generated a negative expected return over the last 90 days | |
| Kezar Life Sciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 7 M. Reported Net Loss for the year was (101.87 M) with loss before taxes, overhead, and interest of (72.35 M). | |
| Kezar Life Sciences has about 306.84 M in cash with (81.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.49. | |
| Kezar Life Sciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 62.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Klearman Micki of 52000 shares of Kezar Life at 2.28 subject to Rule 16b-3 |
- Analyzing Kezar Life's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kezar Life's stock is overvalued or undervalued compared to its peers.
- Examining Kezar Life's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kezar Life's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kezar Life's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kezar Life's stock. These opinions can provide insight into Kezar Life's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Kezar Stock Analysis
When running Kezar Life's price analysis, check to measure Kezar Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kezar Life is operating at the current time. Most of Kezar Life's value examination focuses on studying past and present price action to predict the probability of Kezar Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kezar Life's price. Additionally, you may evaluate how the addition of Kezar Life to your portfolios can decrease your overall portfolio volatility.